Drug Profile


Alternative Names: ALTU-135; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics
  • Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
  • Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
  • Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Exocrine pancreatic insufficiency

Most Recent Events

  • 14 Aug 2017 The European Cystic Fibrosis Society Clinical Trial Network Executive Committee approves the phase III RESULT study in Exocrine pancreatic insufficiency due to cystic fibrosis
  • 28 Apr 2017 Anthera Pharmaceuticals initiates the phase III RESULT trial in Exocrine pancreatic insufficiency (In children, In adolescents, In adults) in USA (NCT03051490)
  • 29 Mar 2017 Efficacy and adverse events data from a long term observation of phase III SOLUTION trial in Exocrine pancreatic insufficiency released by Anthera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top